The Importance of an NCI SPORE Grant

Jeffrey S. Weber, MD, PhD
Published Online: October 31, 2013
Jeffrey S. Weber, MD, PhD, medical oncologist, Department of Cutaneous Oncology, director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, comments on the importance of a Specialized Programs of Research Excellence (SPORE) grant.

Clinical Pearls

  • A Specialized Programs of Research Excellence (SPORE) grant is given out by the NCI
  • SPORE grants bring together investigators from all different disciplines focused on one histology
  • As a part of the SPORE grant given to Moffitt Cancer Center, each project has preclinical laboratory pieces leading to a clinical trial
  • Two out of three SPORE projects at Moffitt currently have clinical trials ongoing


Related Articles
The MEK inhibitor cobimetinib has received an FDA priority review for use in combination with the BRAF inhibitor vemurafenib (Zelboraf) to treat patients with BRAF V600–positive advanced melanoma.
An international team of scientists has shed additional light on the important role of Yes-associated protein (YAP) in tumor development and in treatment response.
The FDA has scheduled a hearing to discuss the biologics license application (BLA) for the immunotherapy talimogene laherparepvec (T-VEC) as a treatment for patients with metastatic melanoma.
The risk of death was significantly reduced for patients with BRAFV600E/K mutation-positive metastatic melanoma treated with dabrafenib and trametinib compared with dabrafenib alone.
JTT Articles
Soft Tissue Sarcomas: Emerging and Novel Concepts
BioT3 Integrates Diagnosis With Actionable Biomarkers in Metastatic Cancer
External Resources

MJH Associates
AJMC
Cure
HCPLive
OncLive
Pharmacy Times
Specialty Pharmacy Times
Physicians' Education Resource
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2015
Intellisphere, LLC. All Rights Reserved.